KARABELAS ARGERIS N 4

What Happened

• Argeris N. Karabelas, a director of REGENXBIO, received equity awards on May 29, 2026: 9,807 restricted stock units (RSUs) and a 46,600-unit derivative award (reported as an award/grant, code A). Both awards were granted at $0.00 per share (typical for compensation grants) and the filing reports $0 acquisition cost. These are grants/awards, not open-market purchases or sales.

Key Details

• Transaction date: May 29, 2026; Form 4 filed June 2, 2026 (filed within the required two business days).
• Awards: 9,807 RSUs (footnote F1) and 46,600 derivative units/options (footnote F2). Combined units awarded = 56,407.
• Price: $0.00 per share as reported (no cash paid at grant).
• Vesting/footnotes:
  • F1 (RSU): 100% of the 9,807 RSUs vest on May 29, 2027, subject to continuous service.
  • F2 (Derivative/option): vests in 12 equal monthly installments beginning May 29, 2027, subject to continuous service.
• Shares owned after transaction: Not specified in the public Form 4 filing.
• Filing timeliness: Filing date (6/2/2026) is within the SEC two-business-day requirement following the 5/29/2026 transaction.

Context

• These awards are standard time-based equity compensation: RSUs convert to underlying shares at vesting, while the derivative award appears to be an option-like grant that vests monthly starting 5/29/2027. No exercise or sale occurred — this is a grant, not an indicator of a purchase or sale. For retail investors, such grants are common for directors and reflect compensation/retention rather than an immediate trading signal.